(Q48938768)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26432858%20AND%20SRC:MED&resulttype=core&format=json

25 February 2020

title

PML risk stratification using anti-JCV antibody index and L-selectin (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26432858%20AND%20SRC:MED&resulttype=core&format=json

25 February 2020

1 reference

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26432858%20AND%20SRC:MED&resulttype=core&format=json

25 February 2020

Frauke Zipp

18

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26432858%20AND%20SRC:MED&resulttype=core&format=json

25 February 2020

Renaud Du Pasquier

20

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26432858%20AND%20SRC:MED&resulttype=core&format=json

Tilman Schneider-Hohendorf

25 February 2020

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26432858%20AND%20SRC:MED&resulttype=core&format=json

25 February 2020

Dennis Görlich

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26432858%20AND%20SRC:MED&resulttype=core&format=json

25 February 2020

Volker Siffrin

13

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26432858%20AND%20SRC:MED&resulttype=core&format=json

25 February 2020

Xavier Montalban

16

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26432858%20AND%20SRC:MED&resulttype=core&format=json

25 February 2020

Christoph Kleinschnitz

21

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26432858%20AND%20SRC:MED&resulttype=core&format=json

25 February 2020

Antonio Bertolotto

24

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26432858%20AND%20SRC:MED&resulttype=core&format=json

25 February 2020

Heinz Wiendl

26

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26432858%20AND%20SRC:MED&resulttype=core&format=json

25 February 2020

19

Ralf Gold

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26432858%20AND%20SRC:MED&resulttype=core&format=json

25 February 2020

14

Felix Luessi

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26432858%20AND%20SRC:MED&resulttype=core&format=json

25 February 2020

17

Sven G Meuth

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26432858%20AND%20SRC:MED&resulttype=core&format=json

25 February 2020

8

Björn Tackenberg

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26432858%20AND%20SRC:MED&resulttype=core&format=json

25 February 2020

author name string

Béatrice Pignolet

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26432858%20AND%20SRC:MED&resulttype=core&format=json

25 February 2020

Michela Spadaro

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26432858%20AND%20SRC:MED&resulttype=core&format=json

25 February 2020

Ingrid Meinl

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26432858%20AND%20SRC:MED&resulttype=core&format=json

25 February 2020

Susanne Windhagen

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26432858%20AND%20SRC:MED&resulttype=core&format=json

25 February 2020

Johanna Breuer

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26432858%20AND%20SRC:MED&resulttype=core&format=json

25 February 2020

Ester Cantó

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26432858%20AND%20SRC:MED&resulttype=core&format=json

25 February 2020

Tania Kümpfel

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26432858%20AND%20SRC:MED&resulttype=core&format=json

25 February 2020

Reinhard Hohlfeld

12

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26432858%20AND%20SRC:MED&resulttype=core&format=json

25 February 2020

Anita Posevitz-Fejfár

15

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26432858%20AND%20SRC:MED&resulttype=core&format=json

25 February 2020

Annett Jacobi

22

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26432858%20AND%20SRC:MED&resulttype=core&format=json

25 February 2020

Manuel Comabella

23

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26432858%20AND%20SRC:MED&resulttype=core&format=json

25 February 2020

David Brassat

25

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26432858%20AND%20SRC:MED&resulttype=core&format=json

25 February 2020

publication date

2 October 2015

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26432858%20AND%20SRC:MED&resulttype=core&format=json

Multiple Sclerosis Journal

25 February 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26432858%20AND%20SRC:MED&resulttype=core&format=json

25 February 2020

volume

22

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26432858%20AND%20SRC:MED&resulttype=core&format=json

25 February 2020

issue

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26432858%20AND%20SRC:MED&resulttype=core&format=json

25 February 2020

page(s)

1048-1060

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26432858%20AND%20SRC:MED&resulttype=core&format=json

A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis

25 February 2020

cites work

1 reference

https://api.crossref.org/works/10.1177%2F1352458515607651

A controlled trial of natalizumab for relapsing multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458515607651

Progressive multifocal leukoencephalopathy and other disorders caused by JC virus: clinical features and pathogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458515607651

Sorting out the risks in progressive multifocal leukoencephalopathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458515607651

Risk of natalizumab-associated progressive multifocal leukoencephalopathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458515607651

Does risk stratification decrease the risk of natalizumab-associated PML? Where is the evidence?

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458515607651

Switch to natalizumab versus fingolimod in active relapsing-remitting multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458515607651

Anti-JC virus antibody levels in serum or plasma further define risk of natalizumab-associated progressive multifocal leukoencephalopathy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458515607651

L-selectin is a possible biomarker for individual PML risk in natalizumab-treated MS patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458515607651

Risk factors for rare diseases can be risky to define: PML and natalizumab

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458515607651

Specific loss of cellular L-selectin on CD4(+) T cells is associated with progressive multifocal leukoencephalopathy development during HIV infection.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458515607651

A second-generation ELISA (STRATIFY JCV™ DxSelect™) for detection of JC virus antibodies in human serum and plasma to support progressive multifocal leukoencephalopathy risk stratification

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458515607651

Identification and quantitation of apoptotic cells following anti-CD3 activation of murine G0 T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458515607651

MiR-126: a novel route for natalizumab action?

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458515607651

Lipid-specific immunoglobulin M bands in cerebrospinal fluid are associated with a reduced risk of developing progressive multifocal leukoencephalopathy during treatment with natalizumab

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458515607651

Association between soluble L-selectin and anti-JCV antibodies in natalizumab-treated relapsing-remitting MS patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458515607651

BK virus antibody titers and intensity of infections after renal transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458515607651

Neutralization serotyping of BK polyomavirus infection in kidney transplant recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458515607651

Positive correlation between Merkel cell polyomavirus viral load and capsid-specific antibody titer

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458515607651

Natalizumab treatment reduces L-selectin (CD62L) in CD4+ T cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458515607651

Anti-JC virus antibodies: implications for PML risk stratification

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458515607651